In the press release, FSD Pharma discussed the launch of a new research and development program targeting unmet medical needs for alcohol misuse and deliberately omitted the underlying misappropriation. District Court for the Southern District of Florida, the complaint alleges that after seven months of exploring a business opportunity of mutual interest and benefit revolving around GBB’s blood alcohol detoxification drink, FSD Pharma publicly announced the misappropriation of GBB’s trade secrets to current and prospective investors in one of its press releases. GBB Drink Lab (“GBB” or the “Company”), maker of the world’s first formulated drink that aids in rapid blood alcohol detoxification, has announced that the Company has filed a lawsuit against FSD Pharma (NASDAQ: HUGE) (“FSD”), a publicly traded biotechnology company that operates in the pharmaceutical research and development business.Īs a result of FSD Pharma’s failure to comply with a Cease-and-Desist letter sent by GBB on April 14 th, 2023, the Company has subsequently filed a $53 million complaint for material breach of a mutual nondisclosure agreement and trade secret misappropriation.įiled on May 1 st, 2023, in the U.S.

The jackson laboratories download